All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Must have received: antimyeloma therapy

Relapse is defined as the progression of disease after an initial response (≥MR) to prior therapy 60 days after cessation of therapy. Refractory disease is defined as a <25% reduction in M protein or disease progression during treatment or within 60 days of stopping treatment.

Cannot have received: antimyeloma therapy

Subjects have received antimyeloma therapy within 2 weeks or 5 pharmacokinetic half-lives, whichever is longer, prior to initiation of treatment. This includes subjects who received a cumulative dose of corticosteroids greater than or equal to a 140 mg prednisone equivalent dose or a single dose of corticosteroids greater than or equal to a 40 mg/day dexamethasone equivalent dose within 2 weeks prior to initiation of treatment.

Cannot have received: allogeneic stem cell transplant

Exception: allowed if >1 year prior to enrollment and no immunosuppressive medications within 1 month prior

Subjects who have previously received an allogeneic stem cell transplant within 1 year prior to the date of enrollment and have not used immunosuppressive medications within 1 month prior to the date of enrollment.